TGFBR1 and neoplasm: Long-Acting Tumor-Activated Prodrug of a TβRI Inhibitor: To increase the therapeutic window of TβRI kinase inhibitors, Zhang and colleagues recently [421] designed TβRI kinase inhibitor prodrugs preferentially activated in tumors over normal tissue based on cleavage and subsequent activation by proteases far more abundant in tumors than normal tissues.